Linden Thomas Advisory Services LLC Acquires 1,630 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Linden Thomas Advisory Services LLC raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 44,531 shares of the biopharmaceutical company’s stock after acquiring an additional 1,630 shares during the period. Gilead Sciences makes up 0.5% of Linden Thomas Advisory Services LLC’s holdings, making the stock its 28th largest position. Linden Thomas Advisory Services LLC’s holdings in Gilead Sciences were worth $4,113,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in GILD. nVerses Capital LLC bought a new stake in Gilead Sciences in the third quarter valued at approximately $25,000. Valued Wealth Advisors LLC increased its position in shares of Gilead Sciences by 101.9% in the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares in the last quarter. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences during the 4th quarter worth $29,000. Strategic Investment Solutions Inc. IL bought a new position in Gilead Sciences during the second quarter worth about $33,000. Finally, Quarry LP bought a new position in Gilead Sciences during the second quarter worth about $43,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now directly owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 456,234 shares of company stock worth $42,130,461. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on GILD shares. Mizuho raised their price target on Gilead Sciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research report on Thursday, November 21st. Truist Financial raised their target price on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a report on Friday, November 8th. Oppenheimer upped their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $80.00 target price on shares of Gilead Sciences in a research note on Wednesday, December 11th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $97.96.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $93.07 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The firm has a fifty day simple moving average of $91.74 and a 200 day simple moving average of $84.86. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $98.90. The stock has a market capitalization of $115.99 billion, a PE ratio of 1,034.11, a P/E/G ratio of 1.31 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. During the same period in the previous year, the business earned $2.29 EPS. Gilead Sciences’s revenue for the quarter was up 7.0% compared to the same quarter last year. On average, research analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a $0.77 dividend. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. Gilead Sciences’s payout ratio is 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.